Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration.
- 1 March 1984
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 2 (3) , 215-220
- https://doi.org/10.1200/jco.1984.2.3.215
Abstract
VP 16-213 in standard doses is active against a number of solid tumors. Its penetration into the cerebrospinal fluid (CSF) is very limited at these dose levels. In 10 patients treated with high-dose VP 16-213 (0.9-2.5 g/m2), CSF levels of up to 0.54 microgram/mL were detected. In two patients with central nervous system (CNS) metastases of small cell lung cancer (SCLC) a response was seen after 1.0 and 1.5 g/m2 intravenously. High-dose VP 16-213 can possibly play a role in the treatment of CNS metastases of SCLC. Its application in late intensification regimens as a form of prophylaxis of CNS metastases should be investigated.This publication has 7 references indexed in Scilit:
- Monitoring of Methotrexate Delivery in Patients with Malignant Brain Tumors After Osmotic Blood-Brain Barrier DisruptionAnnals of Internal Medicine, 1981
- VP-16–213 salvage therapy for refractory germinal neoplasmsCancer, 1980
- Infection prevention in granulocytopenic patients by selective decontamination of the digestive tractPublished by Elsevier ,1980
- A randomized combined modality trial in small cell carcinoma of the lung comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiationCancer, 1980
- CNS metastases in small cell bronchogenic carcinoma.Increasing frequency and changing pattern with lengthening survivalCancer, 1979
- VP-16-213 MONOTHERAPY FOR REMISSION INDUCTION OF SMALL CELL LUNG-CANCER - RANDOMIZED TRIAL USING 3 DOSAGE SCHEDULES1978
- PHASE-2 CLINICAL-TRIAL WEEKLY ADMINISTRATION OF VP-16-213 IN SMALL CELL BRONCHOGENIC CARCINOMA1977